The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor shot. Moderna said its own vaccine, dubbed ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...